Nephron Sterile Compounding Center (Nephron Pharmaceuticals Corporation), West Columbia, SC

Is Nephron Sterile Compounding Center (Nephron Pharmaceuticals Corporation) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.

Does Nephron Sterile Compounding Center (Nephron Pharmaceuticals Corporation) hold a South Carolina pharmacy license?

State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026. The California State Board of Pharmacy also lists nonresident license NSF 102 for Nephron Sterile Compounding Center Llc, West Columbia, SC, status Active, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0000038 for Nephron Sterile Compounding Center, LLC, WEST COLUMBIA, SC, status Active, as of Nov 10, 2026.

Has Nephron Sterile Compounding Center (Nephron Pharmaceuticals Corporation) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Oct 21, 2022) and 2 FMD-145 letters (May 17, 2019 and Apr 13, 2022) for Nephron Sterile Compounding Center (Nephron Pharmaceuticals Corporation). State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Nephron Pharmaceuticals Corporation; Nephron Sterile Compounding Center
Location
West Columbia, SC
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
1
Latest action on that page
Sep 25, 2024
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 9 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Nephron Pharmaceuticals Corporation, dba Nephron Sterile Compounding Center, LLC, a 503B facility, with 8 dated actions.

Document
Sep 25, 2024Form 483483 Issued 09/25/2024FDA copy (archived)
Nov 16, 2023Regulatory meetingRegulatory Meeting Held 11/16/2023Not linked by FDA
Feb 10, 2023Form 483483 Issued 02/10/2023FDA copy (archived)
Oct 21, 2022Warning letterWarning Letter Issued 10/21/2022FDA copy (archived)
Apr 20, 2022Form 483483 Issued 04/20/2022FDA copy (archived)
Apr 13, 2022FMD-145 letterFMD-145 Letter Issued 04/13/2022Not linked by FDA
Nov 15, 2019Form 483483 Issued 11/15/2019fda.gov
May 17, 2019FMD-145 letterFMD-145 Letter Issued 05/17/2019Not linked by FDA

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 9 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Nov 15, 2019: 9 observations

Firm on the cover
Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, 4500 12th Street Ext, West Columbia, SC 29172-3025
FEI number
301115838
Establishment type on the cover
503B Outsourcing Facility
FDA district office on the cover
DISTRICT ADDRESS AND PtlONE NUMBER 60 Eighth Street NE Atlanta, GA 30309
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Test procedures relative to appropriate laboratory testing for sterility are not written and followed.

Specifically, the firm's written procedures for conducting <Redacted B4> rapid sterility testing are deficient in that:

l. Finished drug product <Redacted B4> rapid sterility test samples deemed by firm personnel to be "background too high", verbally defined as samples displaying more than <Redacted B4> events, are not fully examined. The firm discards the sample results and the product lot is <Redacted B4> If this <Redacted B4> "background too high", the firm will <Redacted B4> No investigations are conducted for test deemed as "background too high". Samples have been deemed "background too high" approximately 23 times in the last 90 days. Additionally, during the execution of rapid sterility sample preparation on November 4, a laboratory analyst was observed practicing poor aseptic technique including passing their hands over open containers and exposed samples on at least three occasions, which could lead to the introduction of microbial and particulate contamination of the samples.

2. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followw.

Specifically,

1. " Your firm fai led to follow SOP.CM.4 102, Version 6 (dated: 6/3/19) entitled, "Aseptic ~ Processing and Technique", Section: 6.3.2 PrincipJes of Aseptic Technique as evidenced by tbe following examples:

a. According to your <Redacted B4> on 10/26/19, at approximately <Redacted B4> during the filling of Succinylcholine Chloride Injection, USP 200mg/l OmL (preservative free), lot# SU9083A, the aseptic technique of your firm's operator was not adequate as they were observed opening the Luer Lock IV Syringe Cap containers directly over the firm's <Redacted B4> cap scoop containing caps (product contact surface), blocking first air, then was observed opening the door to the <Redacted B4> filling line and touching the feeder containing the Luer Lock IV Syringe Caps with their gloved hand. In addition, from approximately <Redacted B4> your firm's operators were observed sanitizing their gloved hands prior to personnel monitoring of their sleeves and gloved hands (conducted at approximately <Redacted B4> ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

1. Your firm failed to follow SOP.MB.4501, Version 17 (dated: 8/19/19) entitled, "Environmental and Personnel Monitoring", Section: 6.3.5 Personnel Sampling as evidenced by the following example: on 10/30/19, during personnel monitoring, technicians were observed quickly tapping their fingertips to each media plate, rather than rolling their fingers to capture the gloved hands utilized during aseptic production. In addition, one technician was observed with wet gloves from previously spraying them with <Redacted B4> prior to sampling which is inadequate and not considered representative of aseptic production.

2. Your firm's SOP.MB.4501, Version 17 (dated: 8/19/19) entitled, "Environmental and Personnel Monitoring", Attachment 20'-Sampling for <Redacted B4> inadequate as evidenced by the following example: surface samples are not conducted for <Redacted B4> cap scooper at the completion of the <Redacted B4> filling process <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Written procedures for sampling and testing plans are not followed for each drug product.

Specifically, your firm failed to follow SOP.QC.4301, Version 19 (dated: 8/20/19), Section: 6.5 100% Syringe Visual Inspection as evidenced by the following example: on 10/29/19, your firm's technician was observed exhibiting poor technique while quickly and incompletely inverting the sterile syringes (clear plastic) during the visual inspection process for Phenylephrine HCL Injection, 10 mL lot #PE9194A.

Observation 5

Aseptic processing areas are deficient in that floors and walls are not smooth and/or hard surfaces that are easi1y cleanable.

Specifically, your firm's ISO-7 Clean rooms <Redacted B4> where aseptic processing is performed contain floor drains which appear un-clean and stained. Additionally, on 10/30/19, blue painter's tape was observed affixed to the corner of your firm's clean room wall <Redacted B4> and glass frame covering the gap between areas. The floor drains and blue painter's tape cannot be easily cleaned or sanitized.

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, your firm failed to follow SOP.SR.2501, Version 18.0, Cleaning of Classified Environments for Nephron 503b Outsourcing Facility (dated: 8/15/2019), Section 6 -Procedure, as evidenced by the following example: on 10/28/19, during the formulation ofNeostigmine, lmg/mL (3mL) lot #NE.9066 it was observed that within Compounding Suite <Redacted B4> , Room <Redacted B4> (ISO-7), the base of the loading ramp leading onto the floor production scale contains a black-colored substance and is stained. The cleaning log for that suite <Redacted B4> Floor Cleanroom Cleaning/Sanitization Log, (PR: 1002134), effective 8/28/2019, shows startup cleaning prior to formulation, on 10-28-2019, however the observed growth within the classified area does not support that cleaning within the suite was adequate.

Observation 7

Established test procedures are not documented at the time of performance.

Specifically, The firm does not maintain documentation of the start, stop or elapsed time for the incubation of rapid sterility test <Redacted B4>. The firm only temporarily records start and due/end times on a piece of tape on the box holding the sample <Redacted B4> This tape is discarded following testing. Incubation within established time and temperature specification 1s important in obtaining valid product sterility results.

Observation 8

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

Specifically,

1. The computer systems used to locally store sterility sample results for the firm's <Redacted B4> instruments allows the addition and deletion of files in the directory used for storage of <Redacted B4> data while logged in under the Windows operating system's shared general laboratory user login.

2. According to the firm's Chief Technology Officer <Redacted B4> sterility testing data is supposed to be backed up <Redacted B4>·; however, data file backup did not occur for one of the firm's <Redacted B4> computer systems from August of 2019 to November 4, 2019. During the time since the backup stopped, approximately <Redacted B4> samples runs were conducted on the instrument.

3. The <Redacted B4> system allows for the deletion of the audit trail on the computers. The audit trail prior to August 2019 for one of the <Redacted B4> computers was deleted from one of <Redacted B4> computer systems. The system has been in used since <Redacted B4>.

Observation 9

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, the firm does not conduct investigations when finished product rapid sterility samples are deemed ''background too high". Samples were deemed "background too high" approximately 23 times in the last 90 days, with no investigations performed. The source nor cause of the high event counts have been identified. The product <Redacted B4> without identification of the cause, nor examination to identify the events. In all cases with the exception of a recent "background too high" sample which is currently undergoing <Redacted B4> sterility testing on the <Redacted B4> sampling of the lot, products have been released as passing sterility based on <Redacted B4> or <Redacted B4> sampling passing.

the events. In all cases with the exception of a recent "background too high" sample which is currently undergoing 1@)]1)' sterility testing on the (b} (4 ) sampling of the lot, products have been released as passing sterility basedonl(b) (4n or:(b) (4)] sampling passing.

State board of pharmacy records

State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NSF 102Nonresident Outsourcing FacilityNephron Sterile Compounding Center LlcWest Columbia, SCActive

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0000038Outsourcing Facility-DistributorNephron Sterile Compounding Center, LLCWEST COLUMBIA, SCActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.